Abstract
Lipopolysaccharide (LPS) and lipoteichoic acid (LTA) neutralization constitute potential non-antibiotic treatment strategies for sepsis - a systemic infection-induced inflammatory response. Studies on LPS- and LTA-neutralizing compounds are abundant in literature, and a number of peptides and peptidomimetics appear to display promising activity. However, in this ongoing search for potential antisepsis drug leads, it will be preferable that the assays used by different research groups lead to readily comparable data for the most efficient compounds. Here, we propose and describe standardized methods to be used for testing of novel compounds for their LPS- and LTA-neutralizing capacity with a focus on functional suppression of pro-inflammatory responses in cell-based systems. To best mimic the human in vivo conditions, we suggest the use of freshly isolated human leukocytes combined with an appropriate method for the chosen cytokine (e.g., IL-6 or TNF-α). The described protocols comprise isolation, stimulation, and viability test of the human leukocytes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wellington EMH, Boxell ABA, Cross P, Feil EJ, Gaze WH, Hawkey PM, Johnson-Rollings AS, Jones DL, Lee NM, Otten W (2013) The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis 13:155–165
Theuretzbacher U (2013) Global antibacterial resistance: the never-ending story. J Glob Antimicrob Resist 1:63–69
Jabes D (2011) The antibiotic R&D pipeline: an update. Curr Opin Microbiol 14:564–569
Uppu DS, Ghosh C, Haldar J (2015) Surviving sepsis in the era of antibiotic resistance: are there any alternative approaches to antibiotic therapy? Microb Pathog 80:7–13
Wang G (2014) Human antimicrobial peptides and proteins. Pharmaceuticals 7:545–594
Jarczak J, Kosciuczuk EM, Lisowski P, Strzalkowska N, Jozwik A, Horbanczuk J, Krzyzewski J, Bagnicka E (2013) Defensins: natural component of human innate immunity. Human Immunol 74:1069–1079
Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW (2002) The human antimicrobial peptide LL37 is a multifunctional modulator of innate immune responses. J Immunol 169:3883–3891
Hancock REW, Stahl H-G (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551–1557
Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, Wang A, Lee K, Doria S, Hamill P, Yu JJ, Li Y, Domini O, Guarna MM, Finlay BB, North JR, Hancock REW (2007) An anti-infective peptide that selectively modulates innate immune responses. Nat Biotechnol 25:465–472
Nijnik A, Madera L, Ma S, Waldbrook M, Elliot MR, Easton D, Mayer ML, Mullaly SC, Kindrachuk J, Jenssen H, Hancock REW (2010) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 184:2539–2550
Yeung ATY, Gellatly SL, Hancock REW (2011) Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 68:2161–2176
Hancock REW, Nijnik A, Philpott DJ (2012) Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 10:243–254
Hilchie AL, Wuerth K, Hancock REW (2013) Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 9:761–768
Cohen J (2009) Non-antibiotic strategies for sepsis. Clin Microbiol Infect 15:302–307
Alejandria MM, Lansang MA, Dans LF, Mantaring JB (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev (9):CD001090
Leitman IM (2011) Modulating the inflammatory response in sepsis. J Surg Res 171:e183–e185
van Langevelde P, Kwappenberg KM, Groeneveld PH, Mattie H, van Dissel JT (1998) Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob Agents Chemother 42:739–743
Heumann D, Roger T (2002) Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 323:59–72
Ginsburg I (2002) Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2:171–179
Rockel C, Hartung T (2012) Systematic review of membrane components of Gram-positive bacteria responsible as pyrogens for inducing human monocyte/macrophage cytokine release. Front Pharmacol 3:56
de Tejada GM, Heinbockel L, Ferrer-Espada R, Heine H, Alexander C, Bárcena-Valera S, Goldmann T, Correa W, Wiesmüller K-H, Gisch N, Sánchez-Gómez S, Fukuoka S, Schürholz T, Gutsmann T, Brandenburg K (2015) Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides. Sci Rep 5:14292
Remick DG (2007) Pathophysiology of sepsis. Am J Pathol 170:1435–1444
Castellheim A, Brekke OL, Espevik T, Harboe M, Mollnes TE (2009) Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 69:479–491
Kimbrell MR, Warshakoon H, Cromer JR, Malladi S, Hood JD, Balakrishna R, Scholdberg TA, David SA (2008) Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells. Immunol Lett 118:132–141
Rosenfeld J, Papo N, Shai Y (2006) Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defence peptides. Peptide properties and plausible modes of action. J Biol Chem 281:1636–1643
Pulido D, Nogués MV, Boix E, Torrent M (2012) Lipopolysaccharide neutralization by antimicrobial peptides: a gambit in the innate host defense strategy. J Innate Immun 4:327–336
Sun Y, Shang D (2015) Inhibitory effects of antimicrobial peptides on lipopolysaccharide-induced inflammation. Mediators Inflamm 2015:167572
Wong K-F, Luk JM (2009) Endotoxin-neutralizing peptides as Gram-negative sepsis therapeutics. Protein Pept Lett 16:539–542
Suzuki MM, Matsumoto M, Yamamoto A, Ochiai M, Horiuchi Y, Niwa M, Omi H, Kobayashi T, Takagi T (2010) Molecular design of LPS-binding peptides. J Microbiol Methods 83:153–155
Schuerholz T, Brandenburg K, Marx G (2012) Antimicrobial peptides and their potential application in inflammation and sepsis. Crit Care 16:207
Shukla P, Rao GM, Pandey G, Sharma S, Mittapeeli N, Shegokar R, Mishra PR (2014) Therapeutic interventions in sepsis: current and anticipated pharmacological agents. Br J Pharmacol 171:5011–5031
Shim D-W, Heo K-H, Kim Y-K, Sim E-J, Kang T-B, Choi J-W, Sim D-W, Cheong S-H, Lee S-H, Bang J-K, Won H-S, Lee K-H (2015) Anti-inflammatory action of an antimicrobial model peptide that suppresses the TRIF-dependent signaling pathway via inhibition of toll-like receptor 4 endocytosis in lipopolysaccharide-stimulated macrophages. PLoS One 10:e126871
Wei L, Yang J, He X, Mo G, Hong J, Yan X, Lin D, Lai R (2013) Structure and function of a potent lipopolysaccharide-binding antimicrobial and anti-inflammatory peptide. J Med Chem 56:3546–3556
Nan YH, Lee B-J, Sin SY (2012) Prokaryotic selectivity, anti-endotoxic activity and protease stability of diastereomeric and enantiomeric analogs of human antimicrobial peptide LL-37. Bull Korean Chem Soc 33:2883–2889
Saravanan R, Mohanram H, Joshi M, Domadia PN, Torres J, Ruedl C, Bhattacharjya S (2012) Structure, activity and interactions of the cysteine deleted analog of tachyplesin-1 with lipopolysaccharide micelles: mechanistic insights into outer-membrane permeabilization and endotoxin neutralization. Biochim Biophys Acta 1818:1613–1624
Kaconis Y, Kowalski I, Howe J, Brauser A, Richter W, Razquin-Olazarán I, Inigo-Pestana M, Garidel P, Rössle M, de Tejada GM, Gutsman T, Brandenburg K (2011) Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 100:2652–2661
Pini A, Falciani C, Mantengoli E, Bindi S, Brunetti J, Iozzi S, Rossolini GM, Bracci L (2010) A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J 24:1015–1022
Mas-Moruno C, Cascales L, Cruz LJ, Mora P, Pérez-Payá E, Albericio F (2008) Nanostructure formation enhances the activity of LPS-neutralizing peptides. ChemMedChem 3:1748–1755
Andrä J, Lohner K, Blondelle SE, Jerala R, Moriyon I, Koch MHJ, Garidel P, Brandenburg K (2005) Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem J 385:135–143
Rosenfeld Y, Lev N, Shai Y (2010) Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry 49:853–861
Skovbakke SL, Larsen CJ, Heegaard PMH, Moesby L, Franzyk H (2015) Lipidated α-peptide/β-peptoid hybrids with potent anti-inflammatory activity. J Med Chem 58:801–813
Murugan R, Jacob B, Ahn M, Hwang E, Sohn H, Park H-N, Lee E, Seo J-H, Cheong C, Nam K-Y, Hyun J-K, Jeong K-W, Kim Y, Shin SY, Bang JK (2013) De novo design and synthesis of ultra-short peptidomimetic antibiotics having dual antimicrobial and anti-inflammatory activities. PLoS One 8:e80025
Padhee S, Smith C, Wu H, Li Y, Manoj N, Qiao Q, Khan Z, Cao C, Yin H, Cai J (2014) The development of antimicrobial α-AApeptides that suppress proinflammatory immune responses. ChemBioChem 15:688–694
Li Y, Smith C, Wu H, Padhee S, Manoj N, Cardiello J, Qiao Q, Cao C, Yin H, Cai J (2014) Lipidated cyclic γ-AApeptides display both antimicrobial and anti-inflammatory activity. ACS Chem Biol 9:211–217
Cheng RP, Gellman SH, DeGrado WF (2001) β-peptides: from structure to function. Chem Rev 101:3219–3233
Chongsiriwatana NP, Patch JA, Czyzewski AM, Dohm MT, Ivankin A, Gidalevitz D, Zuckermann RN, Barron AE (2008) Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc Natl Acad Sci U S A 105:2794–2799
Schmitt MA, Weisblum B, Gellman SH (2007) Interplay among folding, sequence, and lipophilicity in the antibacterial and hemolytic activities of α/β-peptides. J Am Chem Soc 129:417–428
Olsen CA, Ziegler HL, Nielsen HM, Frimodt-Møller N, Jaroszewski JW, Franzyk H (2010) Antimicrobial, hemolytic, and cytotoxic activities of selective antimicrobial β-peptoid-peptide hybrid oligomers. ChemBioChem 11:1356–1360
Yang L, Knapp KM, Yang L, Molin S, Franzyk H, Folkesson A (2013) High in vitro antimicrobial activity of β-peptoid-peptide hybrid oligomers against planktonic and biofilm cultures of Staphylococcus epidermidis. Int J Antimicrob Agents 41:20–27
Jahnsen R, Frimodt-Møller N, Franzyk H (2012) Antimicrobial activity of peptidomimetics against multidrug-resistant Escherichia coli: a comparative study of different backbones. J Med Chem 55:7253–7261
Jahnsen RD, Haney EF, Franzyk H, Hancock REW (2013) Characterization of a proteolytically stable multifunctional host defense peptidomimetic. Chem Biol 20:1286–1295
Mancek M, Pristovsek P, Jerala R (2002) Identification of LPS-binding peptide fragment of MD-2, a toll-receptor accessory protein. Biochem Biophys Res Commun 292:880–885
Jiao YL, Wu MP (2008) Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 43:83–87
Ruzin A, Singh G, Severin A, Yang Y, Dushin RG, Sutherland AG, Minnick A, Greenstein M, May MK, Shlaes DM, Bradford PA (2004) Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrob Agents Chemother 48:728–738
Bucki R, Byfield FJ, Kulakowska A, McCormick ME, Drozdowski W, Namiot Z, Hartung T, Janmey PA (2008) Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol 181:4936–4944
Nell MJ, Tjabringa GS, Wafelman AR, Verrijk R, Hiemstra PS, Drijfhout JW, Grote JJ (2006) Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 27:649–660
Cao L, Dai C, Li Z, Fan Z, Song Y, Wu Y, Cao Z, Li W (2012) Antibacterial activity and mechanism of a scorpion venom peptide derivative in vitro and in vivo. PLoS One 7:e40135
Krusong K, Pollpipat P, Supungul P, Tassanakajon A (2012) A comparative study of antimicrobial properties of crustinPm1 and crustinPm7 from the black tiger shrimp Penaeus monodon. Dev Comp Immunol 36:208–215
Epand RF, Sarig H, Mor A, Epand RM (2009) Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl. Biophys J 97:2250–2257
Ruan Y, Shen T, Wang Y, Hou M, Li J, Sun T (2013) Antimicrobial peptide LL-37 attenuates LTA induced inflammatory effect in macrophages. Int Immunopharmacol 15:575–580
Lee S-H, Baek D-H (2012) Antibacterial and neutralizing effect of human β-defensins on Enterococcus faecalis and Enterococcus faecalis lipoteichoic acid. J Endod 38:351–356
Som A, Navasa N, Percher A, Scott RW, Tew GN, Anguita J (2012) Identification of synthetic host defense peptide mimics that exert dual antimicrobial and anti-inflammatory activities. Clin Vacc Immunol 19:1784–1791
Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, Ulmer AJ, Zahringer U, Seydel U, Di Padova F (1994) Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 8:217–225
Williams KL (2007) Endotoxins. In: Williams KL (ed) Pyrogens, LAL-testing and depyrogenation drugs and pharmaceutical sciences, vol 167, 3rd edn. CRC Press, Boca Raton, FL
Morath S, von Aulock S, Hartung T (2005) Structure/function relationships of lipoteichoic acids. J Endotoxin Res 11:348–356
Ryu YH, Baik JE, Yang JS, Kang SS, Im J, Yun CH, Kim DW, Lee K, Chung DK, Ju HR, Han SH (2009) Differential immunostimulatory effects of Gram-positive bacteria due to their lipoteichoic acids. Int Immunopharmacol 9:127–133
Ziegler-Heitbrock HW, Thiel E, Futterer A, Herzog V, Wirtz A, Riethmuller G (1988) Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 41:456–461
Ralph P, Nakoinz I (1977) Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS. J Immunol 119:950–954
Moesby L, Hansen EW, Christensen JD (1997) Pyrogen testing of lipid-based TPN using Mono Mac 6 monocyte cell line and DELFIA. J Clin Pharm Ther 22:327–333
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Skovbakke, S.L., Franzyk, H. (2017). Anti-inflammatory Properties of Antimicrobial Peptides and Peptidomimetics: LPS and LTA Neutralization. In: Hansen, P. (eds) Antimicrobial Peptides. Methods in Molecular Biology, vol 1548. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6737-7_27
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6737-7_27
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6735-3
Online ISBN: 978-1-4939-6737-7
eBook Packages: Springer Protocols